Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 18Sarcoma 15Burkitt Lymphoma 9Breast Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Lymphoma, T-Cell, Peripheral 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Ovarian Neoplasms 6Lymphoma 6Hodgkin Disease 6Endometrial Neoplasms 5Osteosarcoma 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Liposarcoma 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Peritoneal Neoplasms 3Neoplasms 3Leukemia, Biphenotypic, Acute 3Leiomyosarcoma 3Histiocytoma, Malignant Fibrous 3Hemangiosarcoma 3Colorectal Neoplasms 3Uterine Neoplasms 2Stomach Neoplasms 2Sarcoma, Synovial 2

Interventions

Paclitaxel 2tremelimumab 1trastuzumab deruxtecan 1poly ICLC 1pembrolizumab 1osimertinib 1eribulin 1durvalumab 1cemiplimab 1Vascular Endothelial Growth Factor A 1Radiotherapy 1Peptides 1Doxorubicin 1Docetaxel 1Carboplatin 1Capecitabine 1Bevacizumab 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Diabetes Mellitus, Insulin-Dependent, 12 × Doxorubicin × Clear all
NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡